Previous close | 348.75 |
Open | 352.00 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 351.00 - 352.00 |
52-week range | 215.50 - 352.00 |
Volume | |
Avg. volume | 810 |
Market cap | N/A |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 13 Sept 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
KEY FIGURES Revenue in first half of 2024 €703.1M Growth at constant exchange rates and scope1 +11.3% includingcompanion animals +15.1% farm animals +7.0% Growth at constant exchange rates2 +16.2% Overall change +15.2% 1growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the
TERMINATION OF THE LIQUIDITY CONTRACT We inform you of the termination of our liquidity contract since July 1st, 2024. This contact was in place since February 19, 2019 and suspended since February 3rd, 2023. A lifelong commitment to animal healthAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority
Sébastien Huron leaves the company, Habib Ramdani takes over while the Group recruits its next chief executive officer Virbac announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life. The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Séba